Followers | 30 |
Posts | 3306 |
Boards Moderated | 0 |
Alias Born | 08/21/2015 |
Monday, August 29, 2016 11:45:18 PM
On the other hand, pro-140 has a very large market as it targets the R5 strain which makes up 67% of current U.S. HIV patients and 85% of all new U.S. Patients. I couldn't find statistics for the world, but I'm sure the market is there as well. The monotherapy is where pro-140 will make its money as you can get one subcutaneous shot a week (possibly twice or even once a month once full trial data is available) and side effects are literally not existent. I hate to use Charlie Sheen as an example, but he's been the only person to speak publicly about his experience on pro-140. I don't have his quotes, but his life has basically done a 180 degree turn since switching from the typical HAART regime to pro-140. No more headaches, stomach problems, etc. Pro-140 has been proven in a pivotal trial yet for monotherapy or combination therapy, but many patients have experienced success. 10 patients have had their viral loads suppressed for two years on monotherapy and that absolutely is not the result of a placebo effect. Yes, CYDY needs more cash, which mean dilution, and time to get pro-140 to market. Yes, Ibalizumab will get to the market first but that doesn't matter as they technically aren't competing for the same patients. And if somehow they do college for patients it seems a no brainier that patients would choose the once a week, sub cuts lies shot with zero side effects.
In conclusion, both Ibalizumab and pro-140 have their place among treatments for pro-140. But they cannot be compared directly. Pro-140 won't push Ibalizumab off the market and Ibalizumab won't keep pro-140 from taking its share of the HIV treatment market. I'm not here to state that pr0-140 will make any some a millionaire, but to give facts that pro-140 is not a flop, but a promising drug for those suffering from an HIV infection.
Recent CYDY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:01:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:01:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 10:15:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM